Chris Wolf, D.O. has joined Bluetail Medical Group, based in Chesterfield, Missouri. Dr. Wolf is a sports medicine and regenerative orthopedic specialist.
Chris Wolf, D.O. Joins Bluetail Medical Group
1 min read Premium comments
#bluetailmedicalgroup#chriswolf
According to Bluetail, “Dr. Wolf specializes in the treatment of musculoskeletal injuries by utilizing diagnostic ultrasound and ultrasound-guided injections, and regenerative procedures. He is highly trained in osteopathic manipulative treatment and utilizes it as a part of the treatment plan for many musculoskeletal injuries including back, pelvic, and pregnancy-related pain.”
“Dr. Wolf’s training as a rehabilitation physician helps him formulate a comprehensive plan to guide patients to optimum health. In addition to his role with Bluetail Medical Group, Dr. Wolf is team physician for the North American Prospects Hockey League CarShield AAA Hockey teams in St. Louis.”
“Prior to joining Bluetail Medical Group, Dr. Wolf served as an Associate Professor at the University of Missouri where he directed the care of the Brain Injury and Concussion program. He frequently speaks as a guest speaker and teaches at continuing medical education programs across the country.”
“After receiving his medical degree from Kirksville College of Osteopathic Medicine, Dr. Chris Wolf completed his residency in Physical Medicine & Rehabilitation at the University of Missouri-Columbia. Dr. Wolf is board certified in Physical Medicine & Rehabilitation and subspecialty boarded in Brain Injury Medicine. He also has completed a teaching fellowship in Osteopathic Manipulative Medicine.”
Dr. Wolf told OTW, “I am very excited to join Bluetail Medical Group. This opportunity allows me to offer additional cutting-edge regenerative treatment options for my patients with orthopedic and musculoskeletal pain.”
“It was important for me to join an experienced group that offers a comprehensive, non-operative treatment for each patient. Bluetail Medical Group is well established as leaders nationally in the field of regenerative/biologic treatment. This opportunity enables me to incorporate my skills into the practice and learn from the Group’s vast experience in this expanding field of medicine.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.